IP Library Granted Patent US 9,211,346
Granted Patent B2
US 9,211,346 · App. 13/993,359 · Granted Dec 15, 2015

Carrier-linked magnetic nanoparticle drug delivery composition and method of use

Inventor: John B. Weaver (Hanover, NH)
Assignee: TRUSTEES OF DARTMOUTH COLLEGE
A61K47/48815A61K9/0009A61K9/1271A61K41/00A61K41/0028A61K47/48861A61K47/48884B82Y5/00B82Y25/00A61M37/00Y10S977/773Y10S977/906Y10S977/907
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,211,346
App. No.
13/993,359
Granted
Dec 15, 2015
Kind
B2
Abstract

The present invention is a targeted drug delivery composition composed of carrier-linked magnetic nanoparticles. Using an alternating magnetic field, nanoparticles bound to a targeted cell are selectively ruptured thereby releasing therapeutic agents at the desired site of action.

Claims (7)

1. A method for providing a therapeutic agent to a subject comprising administering to a subject in need thereof a carrier-linked magnetic nanoparticle containing a therapeutic agent and a targeting moiety attached to the carrier-linked magnetic nanoparticle, wherein the carrier is a liposome and the therapeutic agent is encapsulated within the carrier-linked magnetic nanoparticle, and wherein the application of an alternating magnetic field to the subject causes liposomes bound to a target cell in the subject to rupture and release therapeutic agent, while unbound liposomes remain intact, thereby providing the therapeutic agent to the subject.

2. The method of claim 1 , wherein the therapeutic agent is a prodrug.

3. The method of claim 1 , further comprising administering a carrier-linked magnetic nanoparticle containing a moiety for activating the prodrug.

4. The method of claim 1 , wherein the liposome comprises at least one cationic phospholipid or cationic lipid.

5. The method of claim 1 , wherein the liposome is modified with polyethylene glycol (PEG).

6. The method of claim 5 , wherein the PEG is present in an amount of 0.1% to 30% by weight, based upon the lipid constituting the liposome.

7. The method of claim 6 , wherein the PEG is present in an amount of 1% to 15% by weight, based upon the lipid constituting the liposome.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 18, 2018
From: DARMOUTH COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046900/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2013
From: WEAVER, JOHN B.
To: TRUSTEES OF DARTMOUTH COLLEGE
Reel/Frame 030595/0788 →
Continuity (2)
Provisional Application 61422285 · Dec 13, 2010
Related Publication 20130302408A1 · Nov 14, 2013